NIAID trial enrolling hospital patients in remdesivir combination therapies

by on

NIAID trial enrolling hospital patients in remdesivir combination therapies
tjordan_drupal
Nov 25, 2020

Over the next several months, the National Institute of Allergy and Infectious Diseases expects to enroll up to 1,500 adult COVID-19 hospital patients who require supplemental oxygen in a global clinical trial that aims to determine whether baricitinib or dexamethasone is more effective at preventing mechanical ventilation or death when administered with remdesivir. One group of participants will receive dexamethasone and remdesivir, and another group will receive remdesivir and baricitinib.

Headline

NIAID trial enrolling hospital patients in remdesivir combination therapies
tjordan_drupal
Nov 25, 2020

Over the next several months, the National Institute of Allergy and Infectious Diseases expects to enroll up to 1,500 adult COVID-19 hospital patients who require supplemental oxygen in a global clinical trial that aims to determine whether baricitinib or dexamethasone is more effective at preventing mechanical ventilation or death when administered with remdesivir. One group of participants will receive dexamethasone and remdesivir, and another group will receive remdesivir and baricitinib.

Novel Coronavirus (SARS-CoV-2/COVID-19)
COVID-19: Caring for Patients and Communities

Headline

VA:F [1.9.7_1111]
Rating: 0.0/10 (0 votes cast)
VA:F [1.9.7_1111]
Rating: 0 (from 0 votes)

Leave a Comment

Previous post:

Next post: